regulatory
confidence high
sentiment negative
materiality 0.80
Orgenesis Inc.: Nasdaq/NYSE listing notice — Orgenesis receives Nasdaq delisting notice after restatement reveals stockholders' deficit of $15.4M
Orgenesis Inc.
- On April 17, 2024, Nasdaq notified Orgenesis it no longer meets the minimum $2.5M stockholders' equity for continued listing (Rule 5550(b)(1)) after restatement.
- A prior second 180-day compliance period was based on reported equity of $12.4M; the restated Sept 30, 2023 period now shows a deficit of $(15.4M).
- Nasdaq stated it cannot accept a compliance plan; Orgenesis plans to timely request a hearing before the Panel, which stays delisting pending the outcome.
- Common stock will remain listed and trading on Nasdaq at least until the hearing process concludes.
- There is no assurance the company will regain compliance or maintain its Nasdaq listing.